LVEF relapse occurred in 37% of patients with previously improved ejection fraction and was independently predicted by type 2 diabetes, left main or LAD disease, and valvular heart disease.
Cohort (n=98)
In patients with heart failure and improved ejection fraction, LVEF relapse is common (37%) and is predicted by T2DM, left main/LAD disease, and valvular heart disease, underscoring the need for continued medical therapy.
Abstract Background Patients with systolic dysfunction with improvement in left ventricular ejection fraction (LVEF) present a more favorable clinical profile when compared to those that maintain dysfunction. However, little is known about the characteristics of patients who “relapse” after LVEF improvement. Purpose Evaluate prevalence, clinical characteristics and outcomes of patients in whom ejection fraction declined after previous improvement. Methods We retrospectively studied patients followed at a heart failure (HF) clinic with LVEF improvement after an initial diagnosis of HF with reduced ejection fraction (EF), which was defined as having an LVEF 40% on follow-up. We then evaluated the presence of LVEF “relapse” in these patients – a decline in LVEF to 50% or 40%, in cases where it recovered to preserved EF or to mid-range EF, respectively. We analysed patient demographics, clinical parameters and outcomes and used logistic regression to assess the predictors of LVEF “relapse”. Results 98 patients were studied, 70 (71%) male, median age 69 (58–76) years. Fifty-four (55%) patients had recovered EF (50%) and in 44 (45%) it had improved to mid-range values. In 36 (37%) occurred LVEF “relapse”: in 10 (10%) patients to an EF 40–50% and in 88 (90%) to an EF40%. Ischemic cardiomyopathy and non-ischemic dilated cardiomyopathy were the main HF aetiologies (38% and 35%, respectively). During a median follow-up of 7 years, 39 (40%) patients had at least one HF hospitalization. Global mortality was 30%, with no significant statistical difference between the two groups. In univariate analysis, HF duration, type 2 diabetes mellitus (T2DM), left main or left anterior descending coronary (LAD) disease, valvular heart disease (VHD) and chronic kidney disease (CKD) predicted LVEF “relapse”. In multivariate analysis, T2DM, left main or LAD disease and VHD were the only predictors of LVEF “relapse” (Table). Conclusion In this group of patients, LVEF “relapse” after it had initially improved was frequent and was predicted by the presence of T2DM, left main or LAD disease and VHD. Despite improved systolic function, these patients remain at high risk, thus the need to maintain treatment. Funding Acknowledgement Type of funding source: None
Esteves et al. (Sun,) conducted a cohort in Heart failure with improved ejection fraction (n=98). LVEF relapse occurred in 37% of patients with previously improved ejection fraction and was independently predicted by type 2 diabetes, left main or LAD disease, and valvular heart disease.